Literature DB >> 30111575

The D' domain of von Willebrand factor requires the presence of the D3 domain for optimal factor VIII binding.

Małgorzata A Przeradzka1, Henriet Meems1, Carmen van der Zwaan1, Eduard H T M Ebberink1, Maartje van den Biggelaar1, Koen Mertens1, Alexander B Meijer2,3.   

Abstract

The D'-D3 fragment of von Willebrand factor (VWF) can be divided into TIL'-E'-VWD3-C8_3-TIL3-E3 subdomains of which TIL'-E'-VWD3 comprises the main factor VIII (FVIII)-binding region. Yet, von Willebrand disease (VWD) Type 2 Normandy (2N) mutations, associated with impaired FVIII interaction, have been identified in C8_3-TIL3-E3. We now assessed the role of the VWF (sub)domains for FVIII binding using isolated D', D3 and monomeric C-terminal subdomain truncation variants of D'-D3. Competitive binding assays and surface plasmon resonance analysis revealed that D' requires the presence of D3 for effective interaction with FVIII. The isolated D3 domain, however, did not show any FVIII binding. Results indicated that the E3 subdomain is dispensable for FVIII binding. Subsequent deletion of the other subdomains from D3 resulted in a progressive decrease in FVIII-binding affinity. Chemical footprinting mass spectrometry suggested increased conformational changes at the N-terminal side of D3 upon subsequent subdomain deletions at the C-terminal side of the D3. A D'-D3 variant with a VWD type 2N mutation in VWD3 (D879N) or C8_3 (C1060R) also revealed conformational changes in D3, which were proportional to a decrease in FVIII-binding affinity. A D'-D3 variant with a putative VWD type 2N mutation in the E3 subdomain (C1225G) showed, however, normal binding. This implies that the designation VWD type 2N is incorrect for this variant. Results together imply that a structurally intact D3 in D'-D3 is indispensable for effective interaction between D' and FVIII explaining why specific mutations in D3 can impair FVIII binding.
© 2018 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  D'–D3; Von Willebrand Disease; Von Willebrand Factor; factor VIII; mass spectrometry

Mesh:

Substances:

Year:  2018        PMID: 30111575     DOI: 10.1042/BCJ20180431

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  3 in total

1.  FVIII half-life extension by coadministration of a D'D3 albumin fusion protein in mice, rabbits, rats, and monkeys.

Authors:  Sabine Pestel; Hans-Wilhelm Beltz; Philipp Claar; Holger Lind; Marcel Mischnik; Elmar Raquet; Arna Andrews; Jason Simmonds; Vesna Tomasetig; Steven K Dower; Anna Tjärnlund-Wolf; Stefan Schulte; Peter M Schmidt; Thomas Weimer
Journal:  Blood Adv       Date:  2020-05-12

2.  D' domain region Arg782-Cys799 of von Willebrand factor contributes to factor VIII binding.

Authors:  Małgorzata A Przeradzka; Josse van Galen; Eduard H T M Ebberink; Arie J Hoogendijk; Carmen van der Zwaan; Koen Mertens; Maartje van den Biggelaar; Alexander B Meijer
Journal:  Haematologica       Date:  2019-09-26       Impact factor: 9.941

3.  Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII.

Authors:  Melanie Demers; Maria M Aleman; Elena Kistanova; Robert Peters; Joe Salas; Ekta Seth Chhabra
Journal:  J Thromb Haemost       Date:  2022-05-22       Impact factor: 16.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.